Cannabinoid CB1 receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat

被引:10
|
作者
Cainazzo, MM [1 ]
Ferrazza, G [1 ]
Mioni, C [1 ]
Bazzani, C [1 ]
Bertolini, A [1 ]
Guarini, S [1 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Biomed Sci, Pharmacol Sect, I-41100 Modena, Italy
关键词
cannabinoid; cannabinoid CB1 receptor antagonist; melanocortin; hemorrhagic shock; (rat);
D O I
10.1016/S0014-2999(02)01487-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Activation of peripheral cannabinoid CB1 receptors contributes to hemorrhagic hypotension, and endocannabinoids produced by macrophages and platelets may be mediators of this effect. A number of studies have provided evidence that functional links exist in the mechanisms of action of cannabinoids and opioid peptides; and opioids too play an important role in the pathophysiology of hemorrhagic hypotension and shock. On the other hand, melanocortin peptides, which are the main endogenous functional antagonists of opioid peptides, have an antishock effect in animals and humans. Thus, we investigated whether an interaction exists between endocannabinoids and the endogenous opioid/antiopioid system also in a condition of hemorrhagic shock and, particularly, whether the blockade of cannabinoid CB1 receptors potentiates the antishock effect of melanocortins, Urethane-anesthetized rats were stepwise bled until mean arterial pressure decreased to, and stabilized at, 21-23 mm Hg. In this model of hemorrhagic shock, which caused the death of all control rats within 30 min after vehicle (tween 80, 5% in saline) injection, the intravenous (i.v.) bolus injection of the cannabinoid CB1 receptor antagonist N-pip -eridino-5-[4-chlorophenyl]-1-[2,4 dichlorophenyl]-4-methyl-3-pyrazolecarboxaniide (SR141716A) increased mean arterial pressure, pulse pressure, respiratory rate and survival rate in a dose-related manner (0.1-3 mg/kg), an almost complete recovery of mean arterial pressure, pulse pressure and respiratory rate, and 100% survival at the end of the observation period (2 h), occurring with the dose of 3 mg/kg. The melanocortin ACTH-(1-24) (adrenocorticotropin) also produced in a dose-related manner (0.02-0.16 mg/kg i.v.) a restoration of cardiovascular and respiratory functions, and increased survival rate, an almost complete recovery and 100% survival at the end of the observation period (2 h) occurring with the dose of 0.16 mg/kg. When a subactive dose of SR141716A (0.2 mg/kg; 30% survival) was associated with a subactive dose of ACTH-(1-24) (0.02 mg/kg; 12% survival), a complete reversal of the shock condition was obtained with 100% survival at the end of the 2-h observation period. The present results show that the concurrent inhibition of both endogenous opioid and cannabinoid systems produces a reversal of hemorrhagic shock more effective than that produced by the inhibition of either of them. These data suggest that functional interactions between endocannabinoids and opioid/antiopioid are at work also in the pathophysiology of hemorrhagic shock. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 50 条
  • [1] CB1 cannabinoid receptor blockade is protective against transient focal cerebral ischemia
    Hillard, CJ
    Muthian, S
    Gross, GJ
    JOURNAL OF NEUROCHEMISTRY, 2003, 87 : 134 - 134
  • [2] CB1 cannabinoid receptor participates in the vascular hyporeactivity resulting from hemorrhagic shock in rats
    Hou Li-chao
    Li Nan
    Zheng Li-na
    Lu Yan
    Xie Ke-liang
    Wang Yue-min
    Ji Gen-lin
    Xiong Li-ze
    CHINESE MEDICAL JOURNAL, 2009, 122 (08) : 950 - 954
  • [3] Cannabinoid CB1 receptor blockade is protective in a rat model of focal cerebral ischemia-reperfusion injury.
    Muthian, S
    Hillard, CJ
    FASEB JOURNAL, 2000, 14 (08): : A1562 - A1562
  • [4] The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
    Haller, J
    Bakos, N
    Szirmay, M
    Ledent, C
    Freund, TF
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 16 (07) : 1395 - 1398
  • [5] Cannabinoid CB1 receptor expression in rat spinal cord
    Farquhar-Smith, WP
    Egertová, M
    Bradbury, EJ
    McMahon, SB
    Rice, ASC
    Elphick, MR
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2000, 15 (06) : 510 - 521
  • [6] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [7] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526
  • [8] CB1 cannabinoid receptor ligands
    Thakur, GA
    Nikas, SP
    Makriyannis, A
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 631 - 640
  • [9] CB1 cannabinoid receptor antagonists
    Barth, F
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 103 - 118
  • [10] The Cannabinoid CB1 Receptor in Schizophrenia
    Borgan, Faith
    Kokkinou, Michelle
    Howes, Oliver
    BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2021, 6 (06) : 646 - 659